Cargando…
Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis
Invasive aspergillosis remains a major cause of death among the immunocompromised population and those receiving long-term immunosuppressive therapy. In light of increased azole resistance, variable outcomes with existing echinocandin monotherapy and combination therapy, and persistent high mortalit...
Autores principales: | Ghannoum, M., Long, L., Larkin, E. L., Isham, N., Sherif, R., Borroto-Esoda, K., Barat, S., Angulo, D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971594/ https://www.ncbi.nlm.nih.gov/pubmed/29610204 http://dx.doi.org/10.1128/AAC.00244-18 |
Ejemplares similares
-
The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation
por: Larkin, Emily, et al.
Publicado: (2017) -
SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis
por: Borroto-Esoda, Katyna, et al.
Publicado: (2017) -
Assessment of the In Vitro Antifungal Activity of SCY-078 Against a Collection of C. parapsilosis Clinical Isolates
por: Barat, Stephen, et al.
Publicado: (2017) -
672. Activity of Ibrexafungerp (Formerly SCY-078) Against Candida auris: In vitro, In Vivo, and Clinical Case Studies of Candidemia
por: Barat, Stephen, et al.
Publicado: (2019) -
SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies
por: Scorneaux, Bernard, et al.
Publicado: (2017)